Apis Mellifera Araneus Diadematus Atropa Belladonn

證據等級: L5

預測適應症: 0 個

Homeopathic Complex (22-Ingredient): Insufficient Data for Repurposing Evaluation

One-Sentence Summary

This submission contains a 22-ingredient homeopathic combination product (including Apis mellifera, Atropa belladonna, Echinacea angustifolia, Lachesis muta venom, mercuric oxide, phosphorus, and others) with no registered approval in the US market. The TxGNN pipeline returned no predicted indications for this compound, and no clinical trial or literature evidence was retrieved. As a result, a meaningful repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None generated
TxGNN Prediction Score	Not available
Evidence Level	L5 — model prediction only (none returned)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN prediction was generated for this compound. Several structural reasons explain this outcome:

No DrugBank anchor. TxGNN relies on DrugBank node embeddings to traverse the knowledge graph. This product has no DrugBank ID, which means it cannot be positioned within the drug–disease network and therefore produces no scored candidates.

Composite identity problem. The submitted identifier is a semicolon-delimited list of 22 distinct substances (honeybee, garden spider, belladonna, hemlock, echinacea, graphite, mercury oxide, oyster shell calcium carbonate, phosphorus, pine twig, pokeweed root, sulfur, pig pituitary gland, thyroid, poison oak leaf, wasp, Virola resin, etc.). These are characteristic of a homeopathic polypharmacy formula. Standard repurposing databases do not index such combinations as a single entity, making graph-based reasoning impossible without decomposition into individual constituents.

Not marketed. With zero regulatory approvals, there is no approved indication from which a mechanistic bridge to a new use can be drawn.

Safety Considerations

Please refer to the package insert for safety information.

Note on component-level toxicity concerns: Several individual ingredients in this combination carry intrinsic hazard signals that would normally require mandatory review — including Atropa belladonna (anticholinergic alkaloids), Conium maculatum (hemlock, neurotoxic piperidine alkaloids), Lachesis muta venom (haemotoxic snake venom), mercuric oxide (heavy metal), and Toxicodendron pubescens (urushiol contact sensitiser). Any future evaluation must include explicit constituent-level toxicological profiling before proceeding.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline returned zero predicted indications because this product has no DrugBank ID and is not representable as a single node in the knowledge graph. Without a machine-readable drug identity and without any regulatory approval history, no repurposing hypothesis can be evaluated.

To proceed, the following is needed:

Decompose the formula — Identify which of the 22 constituents is the active pharmacological driver (if any) and submit each as a separate query to TxGNN
Obtain a DrugBank ID — At least one constituent (e.g., potassium iodide, phosphorus, thyroid extract) may already have a DrugBank entry and can be evaluated independently
Regulatory classification — Confirm whether this product is regulated as a homeopathic drug, dietary supplement, or conventional pharmaceutical in the target jurisdiction, as this determines which data pathways apply
Constituent-level safety review — Mandatory toxicological assessment for belladonna alkaloids, hemlock alkaloids, mercury compounds, and snake venom components before any clinical consideration
Resubmit with individual INN entries or a confirmed single-entity DrugBank ID
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.